These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36703589)

  • 1. Quantitative Analysis for Chinese and US-listed Pharmaceutical Companies by the LightGBM Algorithm.
    Zheng W; Li J; Wang Y; Ye Z; Zhong H; Kot HW; Ouyang D; Chan G
    Curr Comput Aided Drug Des; 2023; 19(6):405-415. PubMed ID: 36703589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whether Green Finance Improves Green Innovation of Listed Companies-Evidence from China.
    Dong Z; Xu H; Zhang Z; Lyu Y; Lu Y; Duan H
    Int J Environ Res Public Health; 2022 Aug; 19(17):. PubMed ID: 36078597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who reports high company performance? A quantitative study of Chinese listed companies in the energy industry.
    Guo D; Chen H; Long R
    Springerplus; 2016; 5(1):2041. PubMed ID: 27995018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of the Consistency Evaluation Policy of Generic Drugs on R&D Investment Intensity of Pharmaceutical Companies-An Empirical Study Based on the Difference-in-Differences Model.
    Wei Y; Zhu J; Qiao J; Zhang D; Chen Y
    Front Public Health; 2022; 10():902025. PubMed ID: 35757628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corporate financialization, financing constraints, and innovation efficiency-Empirical evidence based on listed Chinese pharmaceutical companies.
    Zhu J; Tang Y; Wei Y; Wang S; Chen Y
    Front Public Health; 2023; 11():1085148. PubMed ID: 37124778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Outbreak and Financial Performance of Chinese Listed Firms: Evidence From Corporate Culture and Corporate Social Responsibility.
    Sun Y; Li Y
    Front Public Health; 2021; 9():710743. PubMed ID: 34604155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Occupational Health and Safety Management of Listed Companies in China's Energy Industry Based on the Combined Weight-Cloud Model: From the Perspective of FPE Information Disclosure.
    Wang Y; Chen H; Long R; Jiang S; Liu B
    Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies.
    López-Toro AA; Sánchez-Teba EM; Benítez-Márquez MD; Rodríguez-Fernández M
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33923122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asian innovation in pharmaceutical and medical device industry - beyond tomorrow.
    Jakovljevic M; Wu W; Merrick J; Cerda A; Varjacic M; Sugahara T
    J Med Econ; 2021 Nov; 24(sup1):42-50. PubMed ID: 34915798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of capital structure on the profitability of pharmaceutical companies the case of iran.
    Mohammadzadeh M; Rahimi F; Rahimi F; Aarabi SM; Salamzadeh J
    Iran J Pharm Res; 2013; 12(3):573-7. PubMed ID: 24250664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Determinants of Research and Development Investment in the Pharmaceutical Industry: Focus on Financial Structures.
    Lee M; Choi M
    Osong Public Health Res Perspect; 2015 Oct; 6(5):302-9. PubMed ID: 26730355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance Prediction of Listed Companies in Smart Healthcare Industry: Based on Machine Learning Algorithms.
    Dong B; Wang X; Cao Q
    J Healthc Eng; 2022; 2022():8091383. PubMed ID: 35035859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial aspects and the future of the pharmaceutical industry in the United States of america.
    Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
    Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial performance of China's listed firms in presence of coronavirus: Evidence from corporate culture and corporate social responsibility.
    Zheng F; Zhao Z; Sun Y; Khan YA
    Curr Psychol; 2023; 42(11):8897-8918. PubMed ID: 34400856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
    Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
    Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustainability efficiency assessment of listed companies in China: a super-efficiency SBM-DEA model considering undesirable output.
    Jiang T; Zhang Y; Jin Q
    Environ Sci Pollut Res Int; 2021 Sep; 28(34):47588-47604. PubMed ID: 33893913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
    Kang SY; Bai G; Karas L; Anderson GF
    Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.